SavedAdd your journal

Journals / Sakarya Tıp Dergisi / 2026 / Volume: 16 Issue: 3

Integrated in Silico and in Vitro Analysis of Peroxisome-Related Genes PEX16 and DHRS4 in Hepatocellular Carcinoma

Sema Şabançelebi(ISTANBUL UNIVERSITY-CERRAHPASA)0000-0002-2678-200X
Fatma Kübra Tombultürk(ISTINYE UNIVERSITY)0000-0002-4358-2309
Metehan Karataş(ISTANBUL UNIVERSITY-CERRAHPASA)0000-0002-2760-2445
Hüseyin Enes Derya(ISTINYE UNIVERSITY)0009-0009-1208-2836
Merve Eskici Göç(ISTANBUL UNIVERSITY-CERRAHPASA)0000-0003-0581-7354
Tuğba Soydaş(ISTANBUL AYDIN UNIVERSITY)0000-0002-0684-1906
Matem Tunçdemir(ISTANBUL UNIVERSITY-CERRAHPASA)0000-0002-5300-4449
Pages
—
Publication Date
2026-09-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further validation in patient-derived samples and functional studies are warranted to evaluate their diagnostic and prognostic potential.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, characterized by profound metabolic reprogramming and limited therapeutic options.
📊
Key Findings & Data:This study aimed to investigate the potential involvement of the peroxisome-related genes PEX16 and DHRS4 in HCC by integrating bioinformatics analyses with experimental validation.
💡
Conclusion & Impact:Further validation in patient-derived samples and functional studies are warranted to evaluate their diagnostic and prognostic potential.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatocellular carcinoma · Gene expression · Peroxisome

Abstract

Objective: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, characterized by profound metabolic reprogramming and limited therapeutic options. Peroxisomes are essential metabolic organelles involved in lipid metabolism, redox homeostasis, and detoxification, and increasing evidence suggests that peroxisomal dysfunction contributes to tumor progression. However, the role of peroxisome biogenesis–related genes in HCC remains insufficiently characterized. This study aimed to investigate the potential involvement of the peroxisome-related genes PEX16 and DHRS4 in HCC by integrating bioinformatics analyses with experimental validation. Methods: Differential gene expression analyses were performed using the GEO datasets GSE183349 and GSE14945 to identify peroxisome-associated genes altered in HCC. The expression levels of PEX16 and DHRS4 were subsequently validated in vitro using quantitative real-time PCR (qPCR) in the HepG2 hepatocellular carcinoma cell line and HUVEC cells as controls. Results: Bioinformatics analyses revealed that PEX16 and DHRS4 were significantly upregulated in HCC datasets. Consistent with the in silico findings, qPCR analysis demonstrated significantly increased expression of both genes in HepG2 cells compared with HUVEC cells (PEX16: p=0.0021; DHRS4: p=0.038). The integrated in silico and in vitro analyses demonstrate that PEX16 and DHRS4 are consistently upregulated in hepatocellular carcinoma. Conclusions: These findings suggest that both genes may serve as peroxisome-associated molecular biomarkers reflecting metabolic reprogramming in HCC. Further validation in patient-derived samples and functional studies are warranted to evaluate their diagnostic and prognostic potential.

🔖

Cite This Article

Şabançelebi, S., Tombultürk, F. K., Karataş, M., Derya, H. E., Göç, M. E., Soydaş, T., Tunçdemir, M. (2026). Integrated in Silico and in Vitro Analysis of Peroxisome-Related Genes PEX16 and DHRS4 in Hepatocellular Carcinoma. Sakarya Tıp Dergisi, Volume: 16 Issue: 3. https://doi.org/10.31832/smj.1970660

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (40)

  1. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598-606. doi:10.1016/j.jhep.2022.08.021.
  2. Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 2024;31(8): 1105-12. doi:10.1038/s41417-024-00764-w.
  3. Ding Z, Wang L, Sun J, Zheng L, Tang Y, Tang H. Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances. Front Oncol. 2025;15:1526206. doi:10.3389/fonc.2025.1526206.
  4. Park S, Hall MN. Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications. Exp Mol Med. 2025;57(3):515-23. doi:10.1038/s12276-025-01415-2.
  5. Kumar R, Islinger M, Worthy H, Carmichael R, Schrader M. The peroxisome: an update on mysteries 3.0. Histochem Cell Biol. 2024;161(2):99-132. doi:10.1007/s00418-023-02259-5.
  6. Vinoy N, Huang G, Wallace DF, Subramaniam VN. Peroxisome dysfunction and steatotic liver disease. Int J Mol Sci. 2025;26(17):8303. doi:10.3390/ijms26178303.
  7. Purdue PE, Lazarow PB. Peroxisome biogenesis. Annu Rev Cell Dev Biol. 2001;17:701-52. doi:10.1146/annurev.cellbio.17.1.701.
  8. Kim PK, Mullen RT. PEX16: a multifaceted regulator of peroxisome biogenesis. Front Physiol. 2013;4:241. doi:10.3389/fphys.2013.00241.
  9. Kim JA. Peroxisome Metabolism in Cancer. Cells. 2020;9(7):1692. doi:10.3390/cells9071692.
  10. Kisiela M, Faust A, Ebert B, Maser E, Scheidig AJ. Crystal structure and catalytic characterization of the dehydrogenase/reductase SDR family member 4 (DHRS4) from Caenorhabditis elegans. FEBS J. 2018;285(2):275-93. doi:10.1111/febs.14337.
  11. Passi G, Lieberman S, Zahdeh F, Murik O, Renbaum P, Beeri R, et al. Discovering predisposing genes for hereditary breast cancer using deep learning. Brief Bioinform. 2024;25(4):bbae346. doi:10.1093/bib/bbae346.
  12. National Center for Biotechnology Information. Gene Expression Omnibus (GEO) [Internet]. Bethesda (MD): National Center for Biotechnology Information; [cited 2026 Jul 25]. Available from: https://www.ncbi.nlm.nih.gov/geo
  13. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna (Austria): R Foundation for Statistical Computing; [cited 2026 Jul 25].
  14. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12(2):115-21. doi:10.1038/nmeth.3252.
  15. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115. doi:10.1093/nar/gks596.
  16. Wang Q, Liu J, Chen Z, Zheng J, Wang Y, Dong J. Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: a comprehensive review. Biomed Pharmacother. 2024;170:116021. doi:10.1016/j.biopha.2023.116021.
  17. Pratama AM, Sharma M, Naidu S, Bömmel H, Prabhuswamimath SC, Madhusudhan T, et al. Peroxisomes and PPARs: emerging role as master regulators of cancer metabolism. Mol Metab. 2024;90:102044. doi:10.1016/j.molmet.2024.102044.
  18. Wei X, Maharjan Y, Dorotea D, Dutta RK, Kim D, Kim H, et al. Knockdown of PEX16 induces autophagic degradation of peroxisomes. Int J Mol Sci. 2021;22(15):7989. doi:10.3390/ijms22157989.
  19. Wang Y, Xu S, Liu J, Qi P. A novel peroxisome-related gene signature predicts breast cancer prognosis and correlates with T cell suppression. Breast Cancer (Dove Med Press). 2024;16:887-911. doi:10.2147/BCTT.S490154.
  20. Song XH, Liang B, Liu GF, Li R, Xie JP, Du K, et al. Expression of a novel alternatively spliced variant of NADP(H)-dependent retinol dehydrogenase/reductase with deletion of exon 3 in cervical squamous carcinoma. Int J Cancer. 2007;120(8):1618-26. doi:10.1002/ijc.22306.
  21. Su Z, Li R, Song X, Liu G, Li Y, Chang X, et al. Identification of a novel isoform of DHRS4 protein with a nuclear localization signal. Gene. 2012;494(2):161-7. doi:10.1016/j.gene.2011.12.033.
  22. Zhou Y, Li K, Zou X, Hua Z, Wang H, Bian W, et al. LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis. Bioengineered. 2021;12(2):10862-77. doi:10.1080/21655979.2021.1994719.
  23. Tang Z, Li Z, Wu G, Li J, Tan J, Zhu L. Long noncoding RNA DHRS4 antisense RNA 1 suppresses osteosarcoma cell proliferation and promotes apoptosis through a competitive endogenous RNA mechanism. Sci Rep. 2025;15(1):2891. doi:10.1038/s41598-025-87246-7.
  24. Gonzalez FJ, Shah YM. PPARα: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology. 2008;246(1):2-8. doi:10.1016/j.tox.2007.09.030.
  25. Liu T, Yuan Z, Wang H, Wang J, Xue L. Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival. Clin Res Hepatol Gastroenterol. 2022;46(10):101835. doi:10.1016/j.clinre.2021.101835.
  26. Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J Lipid Res. 2010;51(10):2863-95. doi:10.1194/jlr.R005959.
  27. Han JM, Kang JA, Han MH, Chung KH, Lee CR, Song WK, et al. Peroxisome-localized hepatitis Bx protein increases the invasion property of hepatocellular carcinoma cells. Arch Virol. 2014;159(10):2549-57. doi:10.1007/s00705-014-2105-4.
  28. Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, Witcher M, Braverman NE, et al. Peroxisomes and cancer: the role of a metabolic specialist in a disease of aberrant metabolism. Biochim Biophys Acta Rev Cancer. 2018;1870(1):103-121. doi:10.1016/j.bbcan.2018.07.004.
  29. Fan C, Li Y, Zhang W, Wang Y, Li Y, Zheng J, et al. Identification and experimental validation of prognostic signature and peroxisome-related key genes in clear cell renal cell carcinoma. Int J Gen Med. 2025;18:2687-702. doi:10.2147/IJGM.S513102.
  30. Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265-80. doi:10.1038/cr.2017.155.
  31. Chen YL, Chou CW, Liu IH, Wu YH, Chen CY. Endoplasmic reticulum stress modulates therapeutic responses in hepatocellular carcinoma. Chemotherapy. 2025;70(4):177-92. doi:10.1159/000545341.
  32. Cao M, Luo X, Wu K, He X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021;6(1):379. doi:10.1038/s41392-021-00778-y.
  33. Du M, Yu Y, Wang J, Ji C. Autophagy-lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. Int J Mol Sci. 2025;27(1):366. doi:10.3390/ijms27010366.
  34. Ju S, Singh MK, Han S, Ranbhise J, Ha J, Choe W, et al. Oxidative stress and cancer therapy: controlling cancer cells using reactive oxygen species. Int J Mol Sci. 2024;25(22):12387. doi:10.3390/ijms252212387.
  35. Scalabrin M, Turco E, Davigo I, Filadi R, Nogara L, Gherardi G, et al. Alterations in peroxisome-mitochondria interplay in skeletal muscle accelerate muscle dysfunction. Nat Commun. 2025;16(1):9868. doi:10.1038/s41467-025-64833-w.
  36. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, et al. Peroxisomal branched chain fatty acid β-oxidation pathway is upregulated in prostate cancer. Prostate. 2005;63(4):316-23. doi:10.1002/pros.20177.
  37. Simsek D, Hassan GS, Sotgia F, Lisanti MP. Investigating the role of peroxisomes in regulating breast cancer stem cell mechanisms. Int J Mol Sci. 2025;26(23):11389. doi:10.3390/ijms262311389.
  38. Katoch S, Sharma V, Patial V. Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: experimental and clinical scenarios. World J Gastroenterol. 2022;28(28):3535-54. doi:10.3748/wjg.v28.i28.3535.
  39. Fu T, Huan T, Rahman G, Zhi H, Xu Z, Oh TG, et al. Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancer progression. Cell Rep. 2023;42(8):112997. doi:10.1016/j.celrep.2023.112997.
  40. Qiu L, Zhan K, Malale K, Wu X, Mei Z. Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. Genes Dis. 2020;9(1):116-27. doi:10.1016/j.gendis.2020.04.010.